Volastra Therapeutics, founded in New York City, is a clinical-stage biotechnology company with a mission to develop innovative therapies for metastatic cancers by targeting chromosomal instability (CIN). The company's vision is to exploit unique insights into CIN, a hallmark of cancer characterized by chromosome segregation errors during mitosis, to create effective treatments. Volastra's product pipeline focuses on oncology therapeutics designed to address this key vulnerability in cancer cells.

Notable affiliated individuals include leading scientists and industry experts who contribute to Volastra's cutting-edge research and development. The company has secured investments from prominent venture capital firms and strategic partners in the biotech industry. Key achievements include advancing their therapeutic candidates into clinical stages and establishing significant partnerships and deals. Volastra's impact lies in its potential to revolutionize cancer treatment by addressing the fundamental mechanisms driving metastasis.